StudyFinder

Search Results Within Category "Skin Conditions"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
13 Study Matches

A Multicenter, Open-Label, Single Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis: Open Label, 64 weeks study. Injectable medicine. Males/Females 2-11 years with moderate to severe atopic dermatitis. The goal of the study is assess the uptake of the drug by the body and safety of nemolizumab administered with topical corticosteroids.

Participants will attend in person visit at the Dermatology Clinical Trial office. Dr. Zaenglein is the pediatric dermatologist in charge of this research study and will do all skin evaluations. In addition at different time points there will be blood that is drawn, questionnaires to be completed, and ECGs will be performed.

Study coordinator will discuss.

Yes
 

Andrea Zaenglein
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

Female
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT04921345
SITE00001016
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 2-11 years old
Diagnosed with Moderate to Severe Atopic Dermatitis
Willing to attend all study visits and follow directions

Exclusion Criteria:
Certain treatments for atopic dermatitis are not allowed; study coordinator will discuss
Had a documented asthma exacerbation requiring hospitalization in the past 12 months.
Weigh less than 22 pounds
Skin Conditions
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

SELVA: A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations

Microcystic lymphatic malformations (mLMs) are masses of spongy tissue that may have small fluid-filled cysts. They are made of abnormally large or misshapen lymph vessels that do not work correctly. They are usually present at birth and get worse over time. Complications of mLMs include infection, bleeding, leaking of lymphatic fluid, disfigurement, and impaired mobility. The purose of this study is to find out if the study medicine, sirolimus 3.9% topical gel, can help with the treatment of mLMs.

Total duration of the study is approximately 28 weeks, with up to 8 visits (approximately 1 visit per month). 5 visits will occur in person and 3 visits will be phone call visits. You will also complete 2 interviews.Procedures involved in the study include: medical history collection, physical exams, skin assessments, patient interviews, photographs, blood draws (at up to 3 visits), urine tests, and questionnaires.

Yes
 

Andrea Zaenglein
DermatologyClinicalTrials@pennstatehealth.psu.edu 717-531-5136
Dermatology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT06239480
STUDY00024161
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Confirmed diagnosis of microcystic lymphatic malformation
At least 6 years old
Willing to follow all study guidelines

Exclusion Criteria:
Certain treatments are not allowed; coordinator will discuss specific treatments
History of HIV or other immunodeficiency
Skin Conditions
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects

Phase 3, global, randomized, double-blind, placebo-controlled, multi-center study that will evaluate upadacitinib in the treatment of moderate to severe HS in adult and adolescent subjects who have failed to respond to or are intolerant of ant-TNF therapy and/or 1 approved non-anti-TNF-biologic therapy for HS.This study is comprised of a 35-day screening period, a 16 week placebo-controlled, double-blinded treatment period (Period 1), a 20-week re-randomized extension treatment period (Period 2), a 68-week long-term extension treatment period (Period 3) and a 30-day follow-up period.

You will completed 3 study periods over approximately 104 weeks. During that time at different time points you will have your skin examined, ECG, complete questionnaires, and have your labs drawn. In addition you will take the study medication as directed by the research study coordinators.

Yes
 

Andrea Zaenglein
Dermatology Clinical Trials - at dermatologyclinicaltrial@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT05889182
SITE00001422
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
12 years of age and older
2 active HS areas
History of previous use ≥ 1 TNF inhibitor for at least 12 weeks and/or 1 approved non-anti-TNF biologic therapy for HS for at least 16 weeks - study coordinator will discuss
Must agree to use daily wash

Exclusion Criteria:
Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; subjects with a history of gastric banding/segmentation are not excluded. - Study coordinator will discuss
Skin Conditions
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Gorlin Syndrome

Participants 18 years and older who meet the diagnostic criteria for the basal cell nevus (Gorlin) syndrome will be assigned to receive either Patidegib Gel 2% or Placebo (no active medicine) to apply twice daily for 12 months. The assignment will be made according to sex assigned at birth, age, and number of BCC lesions at the treatment area at Baseline. The primary endpoint is a comparison between the 2 treatment arms of the number of new BCCs at Month 12 compared to Baseline. The BCCs will be imaged and tracked consistently throughout the study to identify new BCCs and to confirm their diagnosis by dermoscopy (handheld instrument with a 15x magnification lens and a cross-polarized light source).

Participants will participate in 15 visits over approximately 14 months (attend 6 in person visits along with 9 phone call visits). In addition, participants will receive study medication to apply twice a day for 12 months and undergo clinical tests at various time points, which include blood tests, ECG, complete questionnaires/diary, skin exam and skin photographs.

Compensation is provided for eligible participants.

Yes
 

Elizabeth Billingsley
Samantha Gettle - at dermatologyclinicaltrials@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06050122
STUDY00023809
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be confirmed to have a PTCH1 mutation
Diagnostic criteria present for Gorlin Syndrome
10 BCCs present on face at Randomization (Baseline/Day 1)

Exclusion Criteria:
Certain medications are not allowed during study; study coordinator will discuss
uncontrolled systemic disease
uncontrolled skin disease on the face.
Skin Conditions
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa

This study is a placebo-controlled study testing the effectiveness and safety of a new drug (izokibep) in adults with hidradenitis suppurativa (HS). HS is a condition where painful skin lesions occur, most often in places on the body where there is friction (ex: armpits, under the breasts, buttocks, and groin). These lesions can drain and scar and will often reoccur.

For this study, participants will come to the study site about 17 times over approximately 59 weeks. During these visits, there will information about medical history and medications collected as well as demographic information, physical and skin exams, vital signs, blood and urine lab testing, ECGs, a chest x-ray, questionnaires, and a daily diary.

Yes
 

Joslyn Kirby
Dermatology Clinical Trials - at dermatologyclinicaltrials@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05905783
SITE00001430
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of HS for at least 6 months
HS in at least 2 body sites
Willingness to follow study rules and instructions of study staff

Exclusion Criteria:
History of active IBD
Chronic pain not associated with HS
History of HIV
Skin Conditions
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Assessing the treatment of scalp conditions in adult patients

This study is aiming to identify the differences in medicated hair care practices amongst adult patients with scalp conditions. Typical treatment for scalp conditions involves the continued use of medicated shampoos; however, hair care practices across all ethnic and racial barriers are different. This could impact the effectiveness of these medicated washes if they are by chance not being used frequently enough. To our knowledge, no research has explored hair care practices and their relationship to dermatological conditions that affect the scalp.

Participants will complete a one-time survey that will take approximately 5-10 minutes.

No
 

Lauren Hollins
Tierney Wallace - at twallace3@pennstatehealth.psu.edu
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00015439
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Over 18
Access to email and internet
Have sebhorreic dermatitis, sebopsoriasis, dandruff, or psoriasis of the scalp

Exclusion Criteria:
Any other skin conditions
Any scalp conditions with open wounds or sores
Skin Conditions
Survey(s)
I'm interested
Share via email

Incidence Rates of Hair Loss in Women Who Wear Hijab

The aim of this study is to obtain information regarding the incidence of hair-related concerns in women who wear hijab and to collect information pertaining to factors that could contribute to hair loss in women who wear the hijab.

This survey study will involve a one-time survey that will take 5-10 minutes.

No
 

Matthew Helm
Tierney Wallace - at twallace3@pennstatehealth.psu.edu or 717-531-6117
Dermatology (HERSHEY)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023070
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Wear the hijab
Women
Read and understand English
Ages 18 years and older

Exclusion Criteria:
Do not meet inclusion criteria
Skin Conditions
Not applicable
I'm interested
Share via email

Defining the cellular and molecular signatures that are associated with the clinical heterogeneity of hidradenitis suppurativa

Patients with the clinical diagnosis of mild, moderate to severe Hidradenditis Suppurativa or normal healthy volunteers ages 18 and older to participate in a 1 time study visit. There is no treatment provided but we may gain information for the treatment of HS.

Eligible participants will attend a one time in person visit. During the visit, the study team will ask you to participate in the following activities: collect skin sample, blood sample and cheek swab. Take photographs of your HS lesions.

study coordinator will discuss.

Yes
 

Amanda Nelson
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-1513
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00012908
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years and older
Hidradentitis Suppurativa diagnosis for 3 months
Normal skin participants

Exclusion Criteria:
Patients who are Pregnant
Normal skin participants do not have an autoimmune disease
Participants who do not want to have any of the lesion sampling performed
Skin Conditions
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase I, Single-Center, Double-Blind, Randomized Safety, Tolerability, and Dermal Reactogenicity Study of Higher Doses of PDC-APB in Healthy Volunteers With a History of Contact Dermatitis Due to Poison Ivy Exposure

Phase 1, Double- Blind Study, 15 week study, Patch test and Vaccine Injection, Males/Females 18-65 years old with history of urushiol exposure. The rash or allergic contact dermatitis of poison ivy is recognized as occurring after the exposure to the urushiol oil which is found in the leaves of poison ivy, oak and sumac. Currently there is no preventative treatment for contact dermatitis. The purpose of this study is to find out if the vaccine, PDC-APB can help with the prevention of contact dermatitis.

Yes
 

James Marks
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014416
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Documented history of Poison Ivy (urushiol) exposure with a rash
Willing to follow all study instructions
Attend all study visits

Exclusion Criteria:
use of certain medications not allowed; study coordinator will provide more information
Positive test result of HIV, Hepatitis B or Hepatitis C
Participation in an investigational drug or device study within 30 days prior to screening
There are over the counter medications that are not permitted during the study participation, the study coordinator will discuss the list during the screening process.
Skin Conditions
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Exploratory Trial of Ruxolitinib 1.5% Cream for Early Stage Hidradenitis Suppurativa

Explore all stages of Hidradenitis Suppurativa with a topical medication.

There will be 7 in-person visits and 1 follow-up phone call over a 33 week period. Over the course of the study, the following study procedures will take place: medical history and medication history collection, ECG, lab tests (both blood and urine), photography, skin exams, physical exams, questionnaires, and skin biopsies.

Up to $350

Yes
 

Andrea Zaenglein
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04414514
STUDY00016042
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must have diagnosis of HS for at least 3 months (90 days)
Must have active HS in at least 1 area
Must have negative TB screening assessment
Certain medications can be continued if on stable dose; study coordinator will discuss further.

Exclusion Criteria:
Any other active skin disease or condition that may interfere with assessment of HS
Pregnant (or considering becoming pregnant) or lactating females
Does not have reliable internet access for weekly electronic surveys
Skin Conditions
Prefer not to display
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A randomized, double blind, vehicle-controlled, multicenter Phase II study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of moderate to severe Acne vulgaris in adults with photodynamic therapy (PDT)

Moderate to Severe Acne Vulgaris: Males/Females 16 years and older. You will receive the study drug with either 1 hour or 3 hours between study drug application and illumination. The purpose of this study is to test the effectiveness and safety of the study drug, used at two different incubation times (time starting with administration of study drug until start of the red light illumination).

Subjects will attend in person visits in the Dermatology Clinical Trial Office. Your length of participation will depend on how your acne responds to the first treatment; the length of participation for 3 treatments will be approximately 25 weeks.Throughout the study at different time points Dr. Zaenglein will evaluate your acne, blood will be drawn, photos will be taken, and questionnaires will need to be completed.

Study Coordinator will discuss during phone screen.

Yes
 

Andrea Zaenglein
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT05080764
SITE00001055
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 16 years and older may be eligible to participate.
willingness to stop topical facial treatments other than medical cleansers at least 14 days prior to receiving investigational product.
For females must use an adequate and highly effective or two effective methods of contraception throughout the study. Study coordinator will discuss.

Exclusion Criteria:
History of soy or peanut allergy.
For males- beard or other facial hair that might interfere with the study assessments unless subject agrees to be clean-shaven throughout the entire study period.
Certain medications/treatments not allowed during the study; study coordinator will discuss.
Skin Conditions
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Assessing the impact of post-inflammatory hyperpigmentation on quality of life in people of color

This survey study is looking to see how post-inflammatory hyperpigmentation (PIH) affects quality of life in people with skin of color.

Participants will complete a one-time survey that will ask about post-inflammatory hyperpigmentation.

No
 

Lauren Hollins
Tierney Wallace - at twallace3@pennstatehealth.psu.edu or 717-531-6117
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00021979
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 18-89
Experienced/experiencing post-inflammatory hyperpigmentation

Exclusion Criteria:
Individuals with acanthosis nigricans
Individuals who are not able to understand English
Skin Conditions
Survey(s)
I'm interested
Share via email

Skin pathophysiology of Hidradenitis Suppurativa

The purpose of this research study is to collect skin samples from volunteers with HS and volunteers with healthy skin. The collected skin samples will be processed and compared to each other to see if there are specific differences in the skin between the HS volunteer group and the healthy skin volunteer group.

Participants will need to come to a one-time, in-person visit where biopsies (small skin samples) will be collected.- For participants with HS: Up to 4 biopsies will be collected - For participants with healthy skin: Up to 2 biopsies will be collected

Yes
 

Amanda Nelson
Samantha Gettle - at sgettle2@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00020589
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of hidradenitis suppurativa (HS)
HS lesions present in the armpits and/or groin

Exclusion Criteria:
Participants who are pregnant or are planning to become pregnant
Certain medications are not allowed in this study- the study team will provide details
Skin Conditions
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,